Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease
Ludovico Arcuri(University of Ferrara), Michele Morari(University of Padua), Francesco Longo(New York University), Simone Bido(Vita-Salute San Raffaele University), Girolamo Calò(University of Padua), Erwan Bézard(Centre National de la Recherche Scientifique), Nurulain T. Zaveri(Astraea Therapeutics (United States)), Pierre‐Olivier Fernagut(Inserm), Mariangela Calcagno(University of Ferrara), Riccardo Viaro(University of Ferrara)
Cited by 29
Related Papers
Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy
|Movement Disorders|2017|846
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
|The Lancet Neurology|2015|508
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
|Progress in Neurobiology|2015|472